2 Late-Stage Coronavirus Vaccine Candidates in Limbo
Tremendous progress has been made in advancing coronavirus vaccine candidates through clinical testing. However, late-stage studies for two of the leading candidates, one developed by AstraZeneca (NYSE: AZN) and the other developed by Johnson & Johnson (NYSE: JNJ), are on hold in the U.S. after potential safety issues were observed. In this Fool Live video, Healthcare and Cannabis Bureau Chief Corinne Cardina and longtime Motley Fool contributor Keith Speights discuss the status of these two late-stage coronavirus vaccines that are in limbo and whether or not investors should be concerned.
Source Fool.com
